Metabolic syndrome worsens sarcopenia and reduces nutritional therapy benefits in advanced gastric cancer.

ABSTRACT:

Background

Emerging evidence suggests metabolic syndrome (MetS) exacerbates sarcopenia progression and compromises nutritional interventions, yet its dual role as both etiological driver and therapeutic effect modifier remains uncharacterized. This study investigated MetS-related sarcopenia pathophysiology and assessed its impact on nutritional therapy efficacy in advanced gastric cancer.

Patients and methods

We conducted a dual-phase investigation combining Mendelian randomization (MR) analysis of European-ancestry GWAS data (n = 654,783) with retrospective evaluation of 65 sarcopenic gastric cancer patients receiving chemotherapy and enteral nutrition. MR evaluated causal relationships between individual components of MetS and sarcopenia phenotypes, while clinical a

SUBMITTER: Xu L 

PROVIDER: S-EPMC12568025 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature